carbon monoxide has been researched along with sirolimus in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hansell, DM; Lawson, K; Maher, TM; Nicholson, AG | 1 |
Ahn, H; Hong, BS; Hong, J; Jeong, IG; Kim, CS; Kim, HJ; Lee, JL; Lee, KH; Park, K; Song, C | 1 |
Jones, AM; Julien-Williams, P; Moss, J; Stylianou, M; Taveira-DaSilva, AM | 1 |
Tian, X; Tian, Z; Wang, J; Wu, X; Xu, K; Xu, W | 1 |
Moss, J; Pacheco-Rodriguez, G; Steagall, WK; Stylianou, M | 1 |
5 other study(ies) available for carbon monoxide and sirolimus
Article | Year |
---|---|
Successful treatment of progressive diffuse PEComatosis.
Topics: Adult; Biopsy; Carbon Monoxide; Cell Proliferation; Dyspnea; Female; Genotype; Humans; Lung; Lung Diseases; Respiratory Function Tests; Sirolimus; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity | 2012 |
Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carbon Monoxide; Carcinoma, Renal Cell; Everolimus; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pneumonia; Pulmonary Diffusing Capacity; Respiratory Function Tests; Sirolimus; Treatment Outcome | 2014 |
Rates of change in FEV
Topics: Adolescent; Adult; Carbon Monoxide; Disease Progression; Female; Forced Expiratory Volume; Humans; Lung; Lung Neoplasms; Lymphangioleiomyomatosis; Middle Aged; Premenopause; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2018 |
Clinical characteristics in lymphangioleiomyomatosis-related pulmonary hypertension: an observation on 50 patients.
Topics: Adult; Carbon Monoxide; Echocardiography; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Logistic Models; Lymphangioleiomyomatosis; Male; Middle Aged; Multivariate Analysis; Oxygen; Respiratory Function Tests; Sirolimus | 2019 |
Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Carbon Monoxide; Disease Progression; Female; Forced Expiratory Volume; Humans; Lung; Lymphangioleiomyomatosis; Respiratory Function Tests; Retrospective Studies; Sirolimus | 2019 |